Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
  2. Zhao, Xue Zhi; Smith, Steven; Maskell, Daniel P.; Metifiot, Mathieu; Pye, Valerie E.; Fesen, Katherine; Marchand, Christophe; Pommier, Yves; Cherepanov, Peter; Hughes, Stephen; Burke, Terrence
  3. Journal of Medicinal Chemistry. 2017, SEP 14; 60(17): 7315-7332.
  1. 2.   No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-Infected Patients Receiving Antiretroviral Therapy
  2. Gandhi, R. T.; Coombs, R. W.; Chan, E. S.; Bosch, R. J.; Zheng, L.; Margolis, D. M.; Read, S.; Kallungal, B.; Chang, M.; Goecker, E. A.; Wiegand, A.; Kearney, M.; Jacobson, J. M.; D'Aquila, R.; Lederman, M. M.; Mellors, J. W.; Eron, J. J.; AIDS Clinical Trials Group (ACTG) A5244 Team
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2012, Mar; 59(3): 229-235.
  1. 3.   Molecular Dynamics Approaches Estimate the Binding Energy of HIV-1 Integrase Inhibitors and Correlate with In Vitro Activity
  2. Johnson, B. C.; Metifiot, M.; Pommier, Y.; Hughes, S. H.
  3. Antimicrobial Agents and Chemotherapy. 2012, Jan; 56(1): 411-419.
  1. 4.   Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
  2. Koelsch, K. K.; Boesecke, C.; McBride, K.; Gelgor, L.; Fahey, P.; Natarajan, V.; Baker, D.; Bloch, M.; Murray, J. M.; Zaunders, J.; Emery, S.; Cooper, D. A.; Kelleher, A. D.; Team, P. S.
  3. Aids. 2011, Nov; 25(17): 2069-2078.
  1. 5.   Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
  2. Hare, S.; Smith, S. J.; Metifiot, M.; Jaxa-Chamiec, A.; Pommier, Y.; Hughes, S. H.; Cherepanov, P.
  3. Molecular Pharmacology. 2011, Oct; 80(4): 565-572.
  1. 6.   Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors
  2. Zhao, X. Z.; Maddali, K.; Metifiot, M.; Smith, S. J.; Vu, B. C.; March, C.; Hughes, S. H.; Pommier, Y.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry Letters. 2011, May; 21(10): 2986-2990.
  1. 7.   HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection
  2. Mens, H.; Kearney, M.; Wiegand, A.; Shao, W.; Schonning, K.; Gerstoft, J.; Obel, N.; Maldarelli, F.; Mellors, J. W.; Benfield, T.; Coffin, J. M.
  3. Journal of Virology. 2010, Dec; 84(24): 12971-12981.
  1. 8.   Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy
  2. McMahon, D.; Jones, J.; Wiegand, A.; Gange, S. J.; Kearney, M.; Palmer, S.; McNulty, S.; Metcalf, J. A.; Acosta, E.; Rehm, C.; Coffin, J. M.; Mellors, J. W.; Maldarelli, F.
  3. Clinical Infectious Diseases. 2010, Mar; 50(6): 912-919.
  1. 9.   Diketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality
  2. Zhao, X. Z.; Maddali, K.; March, C.; Pommier, Y.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry. 2009 17(14): 5318-5324.
  1. 10.   Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones
  2. Zhao, X. Z.; Maddali, K.; Vu, B. C.; March, C.; Hughes, S. H.; Pommier, Y.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry Letters. 2009 19(10): 2714-2717.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel